[
    [
        {
            "time": "",
            "original_text": "国信证券：维持华兰生物(002007.SZ)“买入”评级 业绩略低于预期 血制品板块维持稳健",
            "features": {
                "keywords": [
                    "华兰生物",
                    "买入评级",
                    "业绩略低于预期",
                    "血制品板块",
                    "稳健"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药",
                    "血制品"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "国信证券：维持华兰生物(002007.SZ)“买入”评级 业绩略低于预期 血制品板块维持稳健",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "国信证券给维持华兰生物买入评级，2021半年报点评：业绩略低于预期，长期逻辑不改",
            "features": {
                "keywords": [
                    "华兰生物",
                    "买入评级",
                    "2021半年报",
                    "业绩略低于预期",
                    "长期逻辑不改"
                ],
                "sentiment_score": -0.2,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "国信证券给维持华兰生物买入评级，2021半年报点评：业绩略低于预期，长期逻辑不改",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        }
    ]
]